slimvictor
Bluelight Crew
Acetaminophen is associated with rare but severe and sometimes fatal skin reactions at usual doses, the FDA said Thursday.
The agency cited three published reports in which individuals developed Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis (AGEP) following administration of acetaminophen, and later showed skin reactions when rechallenged with the drug.
Additional reports of these syndromes following acetaminophen, but without rechallenge to confirm causality, have been published as well, the FDA noted. In most of the reported cases, acetaminophen was the only drug taken.
Also, a search of adverse event reports submitted to the FDA yielded 91 cases of Stevens-Johnson syndrome or TEN and another 16 cases of AGEP that were linked to acetaminophen. Twelve of those cases were fatal and 67 involved hospitalization.
The FDA said it would order a new warning for labels on all prescription products containing acetaminophen indicating a risk for severe skin reactions, and will request that manufacturers of over-the-counter products add such warnings.
It urged that patients developing skin reactions while taking acetaminophen or any other pain reliever or fever reducer to stop the drug and seek medical attention immediately. Patients who previously experienced such reactions after using acetaminophen should avoid the drug in the future, the FDA said.
cont at
http://www.medpagetoday.com/PainManagement/PainManagement/40792
The agency cited three published reports in which individuals developed Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis (AGEP) following administration of acetaminophen, and later showed skin reactions when rechallenged with the drug.
Additional reports of these syndromes following acetaminophen, but without rechallenge to confirm causality, have been published as well, the FDA noted. In most of the reported cases, acetaminophen was the only drug taken.
Also, a search of adverse event reports submitted to the FDA yielded 91 cases of Stevens-Johnson syndrome or TEN and another 16 cases of AGEP that were linked to acetaminophen. Twelve of those cases were fatal and 67 involved hospitalization.
The FDA said it would order a new warning for labels on all prescription products containing acetaminophen indicating a risk for severe skin reactions, and will request that manufacturers of over-the-counter products add such warnings.
It urged that patients developing skin reactions while taking acetaminophen or any other pain reliever or fever reducer to stop the drug and seek medical attention immediately. Patients who previously experienced such reactions after using acetaminophen should avoid the drug in the future, the FDA said.
cont at
http://www.medpagetoday.com/PainManagement/PainManagement/40792
